Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant Acromegaly
NCT00461149
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
50
Enrollment
OTHER
Sponsor class
Conditions
Acromegaly
Interventions
DRUG:
Octreotide-LAR
Sponsor
Federico II University